AAREY DRUGS & PHARMACEUTICALS
|
AAREY DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.67 | 1.49 | 2.58 | 2.79 | 2.48 |
| CEPS(Rs) | 2.27 | 2.11 | 3.37 | 3.18 | 2.86 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 46.45 | 45.34 | 43.85 | 41.29 | 38.50 |
| Tax Rate(%) | 12.34 | 37.25 | 34.69 | 21.53 | 20.00 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 1.13 | 1.84 | 2.31 | 1.33 | 1.08 |
| EBIT Margin(%) | 2.46 | 2.12 | 2.45 | 3.08 | 3.01 |
| Pre Tax Margin(%) | 1.35 | 1.43 | 2.04 | 2.38 | 2.41 |
| PAT Margin (%) | 1.18 | 0.90 | 1.33 | 1.87 | 1.93 |
| Cash Profit Margin (%) | 1.61 | 1.28 | 1.73 | 2.13 | 2.23 |
| Performance Ratios | |||||
| ROA(%) | 1.58 | 1.41 | 2.74 | 3.05 | 3.41 |
| ROE(%) | 3.82 | 3.33 | 6.31 | 6.98 | 6.65 |
| ROCE(%) | 6.09 | 6.28 | 9.87 | 9.46 | 8.48 |
| Asset Turnover(x) | 1.33 | 1.56 | 2.06 | 1.63 | 1.77 |
| Sales/Fixed Asset(x) | 11.80 | 12.83 | 15.88 | 12.23 | 11.29 |
| Working Capital/Sales(x) | 3.41 | 4.09 | 5.35 | 3.98 | 3.70 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.08 | 0.08 | 0.06 | 0.08 | 0.09 |
| Receivable days | 172.65 | 142.04 | 110.48 | 135.22 | 122.77 |
| Inventory Days | 29.29 | 18.51 | 11.91 | 18.57 | 23.26 |
| Payable days | 124.60 | 108.80 | 86.14 | 102.62 | 72.34 |
| Valuation Parameters | |||||
| PER(x) | 26.76 | 15.93 | 16.03 | 8.33 | 5.37 |
| PCE(x) | 19.64 | 11.24 | 12.30 | 7.30 | 4.65 |
| Price/Book(x) | 0.96 | 0.52 | 0.94 | 0.56 | 0.35 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.39 | 0.23 | 0.24 | 0.21 | 0.16 |
| EV/Core EBITDA(x) | 13.59 | 9.29 | 8.47 | 6.14 | 4.89 |
| EV/EBIT(x) | 15.96 | 10.94 | 9.86 | 6.67 | 5.37 |
| EV/CE(x) | 0.95 | 0.63 | 0.93 | 0.61 | 0.44 |
| M Cap / Sales | 0.32 | 0.14 | 0.21 | 0.16 | 0.10 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -5.57 | -14.98 | 41.43 | 16.10 | -15.40 |
| Core EBITDA Growth(%) | 9.24 | -25.68 | 20.55 | 17.58 | -18.84 |
| EBIT Growth(%) | 9.48 | -26.48 | 12.37 | 19.02 | -19.51 |
| PAT Growth(%) | 24.20 | -42.47 | 0.62 | 12.44 | -11.44 |
| EPS Growth(%) | 12.38 | -42.47 | -7.31 | 12.44 | -11.44 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.24 | 0.33 | 0.13 | 0.19 | 0.20 |
| Current Ratio(x) | 1.70 | 1.61 | 1.73 | 1.67 | 1.81 |
| Quick Ratio(x) | 1.49 | 1.44 | 1.62 | 1.53 | 1.64 |
| Interest Cover(x) | 2.22 | 3.10 | 5.93 | 4.40 | 5.06 |
| Total Debt/Mcap(x) | 0.25 | 0.63 | 0.13 | 0.33 | 0.58 |
Compare Financial Ratios of peers of AAREY DRUGS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AAREY DRUGS & PHARMACEUTICALS | ₹158.5 Cr | -9.7% | -14.7% | 13.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹425,930.0 Cr | -1.4% | -7.1% | 48% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,524.0 Cr | 1.5% | -2.1% | 63% | Stock Analytics | |
| CIPLA | ₹118,828.0 Cr | -3.5% | -5.2% | 18% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,290.0 Cr | -3.9% | -10.1% | 10.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,280.3 Cr | -0.3% | -7.3% | 52.2% | Stock Analytics | |
AAREY DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AAREY DRUGS & PHARMACEUTICALS | -9.7% |
-14.7% |
13.2% |
| SENSEX | -2.4% |
-4.2% |
19.5% |
You may also like the below Video Courses
